中国医科大学学报

中国医科大学学报
  • 中文核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
  • BA、CA收录

中国医科大学学报 ›› 2019, Vol. 48 ›› Issue (8): 673-677.doi: 10.12007/j.issn.0258-4646.2019.08.001

• 论著 •    下一篇

晚期非小细胞肺癌肿瘤生长速率与临床病理特征及预后的相关性

孙翠翠, 张斯萌, 温倜, 曲秀娟, 刘云鹏   

  1. 中国医科大学附属第一医院肿瘤内科, 沈阳 110001
  • 收稿日期:2019-01-07 出版日期:2019-08-30 发布日期:2019-07-16
  • 通讯作者: 刘云鹏 E-mail:ypliu@cmu.edu.cn
  • 作者简介:孙翠翠(1993-),女,硕士研究生.
  • 基金资助:
    国家自然科学基金(31770963);辽宁省中央引导地方科技发展专项资金(2016007010);"重大新药创制"科技重大专项(2017ZX09304025)

Correlation between Tumor Growth Rate and Clinicopathological Features and Prognosis in Advanced Non-Small Cell Lung Cancer

SUN Cuicui, ZHANG Simeng, WEN Ti, QU Xiujuan, LIU Yunpeng   

  1. Department of Medical Oncology, The First Hospital, China Medical University, Shenyang 110001, China
  • Received:2019-01-07 Online:2019-08-30 Published:2019-07-16

摘要: 目的 分析晚期非小细胞肺癌(NSCLC)肿瘤生长速率(TGR)与临床病理特征及预后的相关性。方法 纳入458例诊断时无法行根治性手术切除且经病理学证实的局部晚期或转移性NSCLC患者。回顾性收集相关临床病理参数,测量基线及第1次疗效评价时靶病灶最大直径总和,利用公式计算TGR,分析TGR与临床病理特征的关系,并应用Kaplan-Meier法分析TGR与无进展生存期(PFS)及总生存期(OS)的关系。利用COX风险比例回归模型进行单因素及多因素分析,明确TGR高低对预后的影响。结果 高TGR多见于年龄≥ 60岁(P=0.038)、表皮生长因子受体(EGFR)野生型(P=0.013)、一线首选化疗(P=0.002)的患者。生存分析中,低TGR组中位PFS为8.7个月,高TGR组为4.2个月(P<0.001);低TGR组中位OS为24.6个月,高TGR组为16.4个月(P<0.001);低TGR组的中位PFS及OS明显优于高TGR组。结论 TGR在晚期NSCLC中与年龄、EGFR基因状态及一线治疗方案相关,且具有良好的预后预测价值,高TGR较低TGR人群生存期短,预后差。高TGR可作为影响PFS及OS的独立危险因素。

关键词: 非小细胞肺癌, 肿瘤生长速率, 临床病理特征, 预后

Abstract: Objective To analyze the relationship between tumor growth rate (TGR) and clinicopathological features and prognosis in advanced non-small cell lung cancer (NSCLC). Methods A total of 458 patients with advanced NSCLC who never received radiotherapy or underwent surgery were selected. The clinicopathological features were collected retrospectively,and the sum of the maximum diameter of the target lesions at baseline and at first evaluation was measured. TGR was calculated using a formula. Progression-free survival (PFS) and overall survival (OS) were analyzed by the Kaplan-Meier survival curve. Univariate and multivariate analyses using COX risk proportional regression model were performed to indicate the effects of TGR on the prognosis. Results High TGR occurred frequently in elderly patients (P=0.038),patients with wild-type epidermal growth factor receptor (EGFR) (P=0.013),and patients receiving chemotherapy as the first-line treatment (P=0.002). The median PFS was 8.7 months in the low TGR group and 4.2 months in the high TGR group (P<0.001). The median OS was 24.6 months in the low TGR group and 16.4 months in the high TGR group (P<0.001). The PFS and OS in the low TGR group were significantly better than those in the high TGR group. Conclusion TGR correlated with age,EGFR gene,and first-line treatment,and it has a good prognostic value. The survival of patients with a high TGR is shorter than those with a low TGR. High TGR can be used as an independent risk factor for PFS and OS.

Key words: non-small cell lung cancer, tumor growth rate, clinicopathological feature, prognosis

中图分类号: 

  • R734.2
[1] SIEGEL RL,MILLER KD,JEMAL A. Cancer statistics,2018[J]. CA Cancer J Clin,2018,68(1):7-30. DOI:10.3322/caac.21442.
[2] CHEN W,SUN K,ZHENG R,et al. Cancer incidence and mortality in China,2014[J]. Chin J Cancer Res,2018,30(1):1-12. DOI:10.21147/j.issn.1000-9604.2018.01.01.
[3] GOLDSTRAW P,CROWLEY J,CHANSKY K,et al. The IASLC Lung Cancer Staging Project:proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours[J]. J Thorac Oncol,2007,2(8):706-714. DOI:10.1097/JTO.0b013e31812f3c1a.
[4] CRONIN KA,LAKE AJ,SCOTT S. Annual Report to the Nation on the Status of Cancer,part Ⅰ:National cancer statistics[J]. Cancer,2018,124(13):2785-2800. DOI:10.1002/cncr.31551.
[5] GOMEZ-ROCA C,KOSCIELNY S,RIBRAG V,et al. Tumour growth rates and RECIST criteria in early drug development[J]. Eur J Cancer,2011,47(17):2512-2516. DOI:10.1016/j.ejca.2011.06.012.
[6] FERTE C,FERNANDEZ M,HOLLEBECQUE A,et al. Tumor growth rate is an early indicator of antitumor drug activity in phase Ⅰ clinical trials[J]. Clin Cancer Res,2014,20(1):246-252. DOI:10.1158/1078-0432.CCR-13-2098.
[7] MILELLA M. Optimizing clinical benefit with targeted treatment in mRCC:"tumor growth rate" as an alternative clinical endpoint[J]. Crit Rev Oncol Hematol,2016,102:73-81. DOI:10.1016/j.critrevonc.2016.03.019.
[8] WANG Q,GAO J,WU X. Pseudoprogression and hyperprogression after checkpoint blockade[J]. Int Immunopharmacol,2018,58:125-135. DOI:10.1016/j.intimp.2018.03.018.
[9] CHAMPIAT S,DERCLE L,AMMARI S,et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1[J]. Clin Cancer Res,2017,23(8):1920-1928. DOI:10.1158/1078-0432.CCR-16-1741.
[10] VAN BOCKEL LW,VERDUIJN GM,MONNINKHOF EM,et al. The importance of actual tumor growth rate on disease free survival and overall survival in laryngeal squamous cell carcinoma[J]. Radiother Oncol,2014,112(1):119-124. DOI:10.1016/j.radonc.2014.06.004.
[11] SUZUKI C,BLOMQVIST L,SUNDIN A,et al. The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy[J]. Ann Oncol,2012,23(4):948-954. DOI:10.1093/annonc/mdr350.
[12] YANG W,ZHAO J,HAN Y,et al. Long-term outcomes of facial nerve schwannomas with favorable facial nerve function:tumor growth rate is correlated with initial tumor size[J]. Am J Otolaryngol,2015,36(2):163-165. DOI:10.1016/j.amjoto.2014.10.019.
[13] YOO TK,MIN JW,KIM MK,et al. In vivo tumor growth rate measured by US in preoperative period and long term disease outcome in breast cancer patients[J]. PLoS One,2015,10(12):e0144144. DOI:10.1371/journal.pone.0144144.
[14] LEE SH,KIM YS,HAN W,et al. Tumor growth rate of invasive breast cancers during wait times for surgery assessed by ultrasonography[J]. Medicine (Baltimore),2016,95(37):e4874. DOI:10.1097/MD.0000000000004874.
[15] GRANDE E,MARTINEZ-SAEZ O,GAJATE-BORAU P,et al. Translating new data to the daily practice in second line treatment of renal cell carcinoma:the role of tumor growth rate[J]. World J Clin Oncol,2017,8(2):100-105. DOI:10.5306/wjco.v8.i2.100.
[16] NISHINO M,DAHLBERG SE,FULTON LE,et al. Volumetric tumor response and progression in EGFR-mutant NSCLC patients treated with erlotinib or gefitinib[J]. Acad Radiol,2016,23(3):329-336. DOI:10.1016/j.acra.2015.11.005.
[1] 李玉泽, 刘娜, 佟晶, 金蓉, 陈梅, 卑贵光. 动脉自旋标记灌注对足月缺氧缺血性脑病新生儿预后的预测价值[J]. 中国医科大学学报, 2019, 48(9): 812-816.
[2] 段秋艳, 杜秋红, 宋文玲, 苏嘉利, 徐萍. 血清sTWEAK和MMP-9在急性ST段抬高型心肌梗死患者中的表达及其与预后的关系[J]. 中国医科大学学报, 2019, 48(9): 833-836,851.
[3] 韩苏, 王传合, 佟菲, 杨丽娜, 崔文佳, 孙志军. 基于倾向性评分匹配法评估钠离子浓度对心力衰竭患者预后的影响[J]. 中国医科大学学报, 2019, 48(8): 714-718.
[4] 韩苏, 王传合, 佟菲, 杨丽娜, 崔文佳, 孙志军. 性别差异对射血分数中间型心力衰竭患者预后的影响[J]. 中国医科大学学报, 2019, 48(7): 624-628.
[5] 高翔, 刘志宇, 王梁, 戴志红, 汪鑫, 蔡凯. 术前中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值对非肌层浸润性膀胱癌的预后评估价值[J]. 中国医科大学学报, 2019, 48(7): 638-642.
[6] 孙华屹, 张宏, 丛进春. 结肠癌根治术患者临床特征与预后的相关性分析[J]. 中国医科大学学报, 2019, 48(7): 660-662.
[7] 刘宗昂, 张苏宁. 胸腔镜肺段切除术在治疗早期非小细胞肺癌中的应用[J]. 中国医科大学学报, 2019, 48(7): 663-666.
[8] 杨旸, 王一喆, 郑春雷, 侯科佐, 王晓楠, 胡雪君. 抑制AKT通路对埃克替尼耐药的非小细胞肺癌细胞迁移能力的影响[J]. 中国医科大学学报, 2019, 48(6): 502-506.
[9] 王硕, 郑新宇. 乳腺癌根治术患者化疗相关粒细胞减少与预后的关系[J]. 中国医科大学学报, 2019, 48(6): 542-546.
[10] 董会帅, 范崇渝, 韩云. 肺叶切除与肺段切除治疗肺部磨玻璃结节效果的比较[J]. 中国医科大学学报, 2019, 48(6): 547-550.
[11] 蔡恒, 刘文静, 冯天达, 刘云会. 垂体转移瘤的临床特点及治疗分析:2例病例报道及文献回顾[J]. 中国医科大学学报, 2019, 48(6): 564-567.
[12] 常盼盼, 刘畅, 崇巍. 严重创伤性脑损伤后凝血功能障碍与预后的关系[J]. 中国医科大学学报, 2019, 48(5): 425-429.
[13] 白云鹏, 许顺. 培美曲塞联合铂类一线药物治疗晚期非鳞型非小细胞肺癌的疗效[J]. 中国医科大学学报, 2019, 48(5): 469-471.
[14] 庄莹, 张淑红, 樊伟平, 赵小芳, 孙海燕, 刘爽, 张虎. 乳腺癌中DEAH盒解旋酶16的表达及临床意义[J]. 中国医科大学学报, 2019, 48(4): 305-308.
[15] 胡明, 张淑红, 陈跟林, 凌存宝, 樊伟平, 孙海燕, 刘爽, 张虎. 泛癌症分析DEAH盒解旋酶16的表达及其预后意义[J]. 中国医科大学学报, 2019, 48(3): 201-204.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 贺雪梅, 熊欣, 邹建中, 李发琪, 龚晓波. 超声消融剂量与生物学焦域特征[J]. 中国医科大学学报, 2009, 38(9): 654 .
[2] 孔静, 吴硕东, 范莹, 金俊哲, 石刚. 腹腔镜胰体尾切除及胰腺假性囊肿内引流手术体会[J]. 中国医科大学学报, 2009, 38(9): 690 .
[3] 宋辉. 缺氧诱导因子-1α在喉鳞状细胞癌中的表达及与微血管密度的关系[J]. 中国医科大学学报, 2009, 38(9): 700 .
[4] 夏光, 吕庆杰, 姜卫国, 齐亚飞, 王劲欧. Wnt-1蛋白和β-catenin在卵巢癌中的表达及意义[J]. 中国医科大学学报, 2009, 38(9): 706 .
[5] 郭哲, 徐冰, 卢利. 下颌骨髁突骨折治疗的Meta分析[J]. 中国医科大学学报, 2009, 38(9): 709 .
[6] 夏永辉, 徐克. 对吻式支架置入术治疗Leriche综合征15例体会[J]. 中国医科大学学报, 2009, 38(9): 714 .
[7] 林书坡, 林杰, 史今. 替米沙坦对胰岛素抵抗大鼠肾脏脂联素表达的影响[J]. 中国医科大学学报, 2009, 38(10): 741 .
[8] 高红, 吕良英, 白伟良, 王大佳, 黄英, 张志波, 王维林. 先天性巨结肠组织蛋白质组成分的双向凝胶电泳分析[J]. 中国医科大学学报, 2009, 38(10): 761 .
[9] 张丽, 齐瑞群, 孙艳, 陈国红, 任宏伟, 陈洪铎, 高兴华. 卡介菌多糖核酸对特应性皮炎外周血CLA~+T细胞表达不同细胞因子的影响[J]. 中国医科大学学报, 2009, 38(10): 764 .
[10] 程大丽, 穆庆, 夏志军. 女性压力性尿失禁患者盆底生物反馈治疗36例临床分析[J]. 中国医科大学学报, 2009, 38(10): 778 .

中国医科大学学报版权所有©2018

未经允许,严禁擅自转载本站图文资料

地址:中国 沈阳市沈北新区蒲河路77号 110122

辽ICP备05014850

JOURNAL OF CHINA MEDICAL UNIVERSITY

ADDRESS: NO.77 PUHE ROAD

SHENYANG NORTH NEW AREA, SHENYANG

LIAONING PROVINCE, P.R. CHINA